$RZLT

Global markets are mixed as crude oil prices and bond yields rise. Saudi Arabia aims to restore half of its East-West pipeline capacity, which was shut due to drone strikes. Markets price in a 58% chance of a 25 bp Fed rate hike. Software and cybersecurity stocks fall, while chipmakers and crypto-exposed stocks rise. Netflix drops after a downgrade, and Nucor declines on weaker earnings guidance. Bitcoin gains over 2% after SEC's digital securities plan.

Rezolute reported early results from its rare hypoglycemia (tumor hyperinsulinism) study of ersodetug. The company said 6 of 8 enrolled participants met the primary endpoint, achieving ≥50% reduction in intravenous glucose needs (GIR) during the 8-week pivotal phase and fully stopping IV glucose. One participant withdrew and died after hospice transition and was deemed a non-responder. Rezolute said safety remains favorable and no drug-related adverse events have been reported.

Rezolute Inc. reported positive interim Phase 3 upLIFT results for ersodetug in tumor-related hyperinsulinism. The trial enrolled 8 of 16 planned patients; 6 of the first 8 met the primary endpoint, with ≥50% reductions in IV glucose needs during the 8-week pivotal phase, and all six stopped IV glucose while on treatment. No drug-related adverse events were reported. Rezolute expects topline results in H2 2026.

Rezolute, Inc.'s CFO, Daron Evans, purchased 10,000 common shares in an open-market transaction at $2.85 per share on March 30, 2026. This purchase brings his direct holdings to 414,462 common shares. The filing also details various indirect holdings through his spouse, minor children, and PoC Capital, LLC, for which he disclaims beneficial ownership except for his pecuniary interest.

This article provides current stock price information and CFD trading conditions for Rezolute Inc (RZLT) on Capital.com. It details various financial metrics such as previous close, open price, 1-year change, and day's range, alongside CFD-specific information like spread, overnight funding adjustments, and margin requirements. The page also features recent articles on other stocks and customer reviews for the Capital.com platform.

Rezolute, Inc. (NASDAQ:RZLT) has received a consensus "Hold" recommendation from twelve brokerages, with an average 12-month price target of $9.78. Despite this, recent insider purchases by CEO Nevan Elam and CFO Daron Evans show their confidence, increasing insider ownership to 14.78%. The stock is currently trading at $1.97, significantly below analysts' average target, and showcases high volatility with a diverse range of analyst ratings, including one sell, five hold, and six buy recommendations.

Rezolute Inc. (NASDAQ: RZLT) is experiencing significant investor backlash and legal scrutiny after its stock plunged by nearly 90% due to the unsuccessful sunRIZE clinical trial for ersodetug. Legal firms are investigating potential securities violations, alleging the company misled investors about drug efficacy, while major financial institutions have downgraded the stock and cut price targets. Shareholders are exploring legal options as market confidence plummets following the trial failure and subsequent financial turmoil.

Jefferies has raised its price target for Rezolute to $20 with a Buy rating, driven by anticipated congenital hyperinsulinism data and potential value in tumor hyperinsulinism. Despite a lowered price target from H.C. Wainwright due to previous study outcomes, Rezolute's strategic financial maneuvers and upcoming data are creating a dynamic period for the company. Investors are weighing optimistic projections against market realities as the biotech company navigates both opportunities and challenges.

Rezolute Inc. (NASDAQ: RZLT) stock surged by 15.04% on December 24, 2025, driven by positive drug trial results and an increased price target from Jefferies. While the company shows strong financial management and potential in congenital hyperinsulinism, challenges exist, including a reduced price target from H.C. Wainwright due to unforeseen study results and operational hurdles. Investors are advised to consider both the growth potential and associated risks as the company navigates its pipeline developments and capital adjustments.

Rezolute, Inc. (NASDAQ: RZLT) experienced a 90% share price drop after its lead asset, ersodetug, failed to meet its primary and secondary endpoints in a Phase 3 trial for hypoglycemia caused by hyperinsulinism. This failure has prompted Hagens Berman, a national shareholders rights firm, to investigate whether Rezolute misled investors regarding erso's efficacy and commercial potential. Investors who suffered significant losses are encouraged to submit their information to the firm.